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Background: Nocturia is defined as waking one or more times during the night due to the urge to void. Recently,
the effectiveness of several sedatives and analgesics for nocturia has been reported. We herein investigated the
effects of ramelteon, an antioxidant and sleep inducer, on nocturia unresponsive to α1-blocker monotherapy in
males with lower urinary tract symptoms (LUTS) as a pilot study.
Methods: Subjects were 19 patients who had LUTS suggestive of benign prostate hyperplasia, received α1-blockers
(tamsulosin, silodosin, or naftopidil), and continued to have two or more episodes of nocturia per night before
starting ramelteon. Ramelteon at 8 mg once daily for one month was added to the α1-blocker. A self-administered
questionnaire including the International Prostate Symptom Score (IPSS), quality of life (QoL) index, Overactive
Bladder Symptom Score (OABSS), and Nocturia Quality-of-Life Questionnaire (N-QOL) were assessed before and one
month after starting ramelteon.
Results: The mean score on IPSS question 7 (nocturia) decreased significantly from 2.88 before starting ramelteon
to 2.41 one month after starting the medication (P = 0.03). The mean total OABSS decreased significantly from 6.31
to 5.38 (P = 0.03), and the mean for OABSS question 2 (nighttime frequency of nocturia) also significantly decreased
from 2.63 to 2.13 (P = 0.01). The mean total N-QOL score did not change significantly. Two patients had dizziness;
the remaining patients had no adverse drug-related events.
Conclusions: Ramelteon in combination with an α1-blocker could be a treatment option for reducing nocturia in
men with BPH.
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Nocturia is defined by the International Continence So-
ciety as awaking one or more times a night because of
the urge to void [1]. Nocturia is known to be related to
many other diseases and conditions, including overactive
bladder, benign prostate hyperplasia (BPH), obstructive
sleep apnea and congestive heart failure [2]. Various
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reproduction in any medium, provided the oralcohol intake can also result in an increased urinary
volume at night and increased nocturia [3]. The timing
of therapy with diuretics, beta-blockers and xanthines
may also cause some people to void more frequently at
night [4]. Middelkoop et al. described that nocturia and
associated worries were the most frequent causes of dis-
turbed sleep in adults over the age of 50years [5].
Tsujimura et al. reported that urgency and nocturia are
factors that independently affect sleep quality, which is
closely related to patient quality of life [6]. Moreover,
when nighttime waking occurs two or more times,
nocturia has also been associated with a 10–21% in-
creased risk of falling, limb fracture, excessive daytime
somnolence, and nocturnal enuresis [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
Variables Number (%) or Median (mean±SD)
No. of patients 19
Age, years 72.0 (72.1 ± 10.6)
Prostate vol, mL 37.3 (41.9 ± 25.3)
Serum PSA, ng/mL 3.6 (4.7 ± 4.1)
Uroflowmetry
Peak flow rate, mL/s 10.5 (13.2 ± 10.0)
Average flow rate, mL/s 5.0 (7.1 ± 5.5)
Residual volume, mL 20.0 (20 ± 21.8)
Type of alpha-1-adrenergic
antagonists (blockers)
Tamsulosin (0.2 mg/day) 8 (42.1%)
Silodosin (8 mg/day) 2 (10.5%)
Naftopidil (75 mg/day) 9 (47.4%)
Kawahara et al. BMC Urology 2013, 13:30 Page 2 of 6
http://www.biomedcentral.com/1471-2490/13/30Recently, the effectiveness of some sedatives and anal-
gesics for nocturia has been reported [8]. Drake et al.
reported the effectiveness of melatonin for nocturia in a
randomized, double-blind, placebo-controlled crossover
study in 20 men [9] Shimizu et al. reported that ramelteon
significantly decreased the nocturia for patients who had
both LUTS and insomnia [10]. Ramelteon, the first mela-
tonin receptor agonist approved by the United States and
Japan, is a selective MT1 and MT2 agonist, [11] and its ef-
ficacy and safety for chronic insomnia has been reported
[12,13]. Here we investigated the effects of ramelteon, an
antioxidant and sleep inducer in humans, on nocturia un-
responsive to α1-blocker monotherapy in men with LUTS
as a pilot study.
Methods
Subjects were 19 patients, with a median and mean
(± standard deviation [SD]) age of 72.0 and 72.1±10.6
years, respectively. This study was approved by the Insti-
tutional Review Board of Ohguchi Higashi General Hos-
pital, and written informed consent for participation was
obtained from all patients. All patients with LUTS sug-
gestive of BPH who were taking an α1-adrenoceptor an-
tagonist (tamslosin, silodosin, or naftopidil) for more
than 3months and experiencing two or more episodes
of nocturia per night were examined before being ad-
ministered ramelteon. None of the patients were taking
a 5α-reductase inhibitor or anticholinergic drug. The ex-
clusion criteria included prostate cancer, urinary tract
infection, and stone disease. In this study, no patients
had nocturnal polyuria or sleep disturbances. Ramelteon
was taken at 8mg once daily (at bedtime) for 1month, in
addition to the regular α1-blocker. The type of α1-
blocker was not changed during the study period. A self-
administered questionnaire including the International
Prostate Symptom Score (IPSS), quality of life (QoL)
index, Overactive Bladder Symptom Score (OABSS), and
Nocturia Quality-of-Life Questionnaire (N-QOL) were
assessed before and 1month after starting ramelteon
(Additional files 1, 2, 3 and 4). The IPSS is most com-
monly used as an assessment tool for men with BPH or
OAB, or for those who have undergone radical prosta-
tectomy or prostatic radiotherapy [14-17]. The IPSS
questionnaire comprises seven questions on LUTS (in-
complete emptying, frequency, intermittency, urgency,
weak stream, straining, and nocturia) and an additional
question to yield a QoL index, ranging from zero (de-
lighted) to six (terrible), which was used as the QoL sur-
rogate indicator in this study. OAB is defined as a
symptom syndrome that includes urgency, with or with-
out urgency incontinence, and usually with frequency
and nocturia [18]. N-QOL is a method for measuring
treatment impact on sleep quality and on QoL thorough
the evaluation of any treatment of nocturia [19].Statistical analysis
All continuous variables are expressed as median and
mean ± SD values. Numerical data were compared using
the Wilcoxon Signed Rank Sum test. An analysis of the
difference in the number of patients with nocturia before
and after treatment was performed using McNemar’s
test. A P-value of 0.05 or less was considered significant.
Because this study was a pilot study that evaluated a
small number of patients, sample size calculations and a
multivariate analysis were not performed.
Results
Table 1 shows patient data including the type of α1-
blocker taken and other baseline characteristics includ-
ing age, prostate volume, serum prostate specific antigen
(PSA) levels, and data of uroflowmetry. The data were
distributed normally. In this study, no differences were
noted in age, past history or medication use between the
patients who were likely to respond and those who were
not. There was also no significant difference in nocturia
at baseline between patients taking tamsulosin silodosin
and naftopidil. Five patients had hypertension with anti-
hypertension drugs, three had diabetes mellitus with anti
diabetes mellitus drugs, and three had a medication of a
diuretic. None of the patients who were medicated with
antidiabetes mellitus drugs had neurogenic conditions.
After 1 month of taking ramelteon, mean score on IPSS
question 7 (nocturia) showed improvement, decreasing
significantly from 2.88 ± 0.70 to 2.41 ± 1.00 (P = 0.03).
However, total IPSS and QoL score did not change sig-
nificantly (Table 2). Mean total OABSS also improved,
decreasing significantly from 6.31 ± 2.15 to 5.38 ± 2.16
(P = 0.03), and likewise mean OABSS for question 2
(nighttime frequency of nocturia) decreased significantly
from 2.63 ± 0.50 to 2.13 ± 0.62 (P = 0.01; Table 3). The
mean total N-QOL score did not change significantly.
Table 2 Pre and post IPSS
Variables Median (mean±SD) P value
Pre Post
Q1 1 (1.9 ± 2.0) 1 (1.6 ± 1.7) 0.631
Q2 3 (2.8 ± 1.4) 2 (2.3 ± 1.3) 0.263
Q3 1 (1.9 ± 2.1) 1 (1.3 ± 1.3) 0.603
Q4 2 (1.8 ± 1.6) 1 (1.6 ± 1.5) 0.227
Q5 1 (1.6 ± 1.6) 1 (2.2 ± 1.9) 0.598
Q6 0 (1.1 ± 1.5) 1 (1.2 ± 1.6) 0.756
Q7 3 (2.9 ± 0.7) 2 (2.4 ± 1.0) 0.033*
total score (Q1-7) 15 (15.0 ± 7.9) 11 (12.6 ± 6.0) 0.142
QOL 5 (4.4 ± 1.5) 4 (3.8 ± 1.5) 0.206
*; p < 0.05.
Table 4 Pre and post NQOL score
Variables Median (mean±SD) P
valuePre Post
Q1 1 (1.1 ± 1.2) 1 (1.5 ± 1.2) 0.280
Q2 2 (1.6 ± 1.3) 1 (1.1 ± 1.0) 0.048*
Q3 2 (1.3 ± 1.1) 1 (1.1 ± 1.2) 0.531
Q4 1 (1.1 ± 1.3) 1 (1.0 ± 0.8) 0.709
Q5 1 (1.6 ± 1.6) 0 (0.9 ± 1.2) 0.077
Q6 2 (2.2 ± 1.5) 2 (1.7 ± 1.3) 0.048*
Q7 2 (2.2 ± 1.4) 1 (1.6 ± 1.0) 0.070
Q8 1 (0.7 ± 0.9) 1 (1.1 ± 1.2) 0.136
Q9 1 (1.5 ± 1.5) 1 (1.4 ± 1.3) 0.806
Q10 3 (2.2 ± 1.5) 3 (2.3 ± 1.3) 0.653
Q11 3 (2.3 ± 1.5) 3 (2.4 ± 1.2) 0.634
Q12 3 (2.3 ± 1.4) 2 (2.1 ± 1.1) 0.510
Q13 4 (4.5 ± 3.1) 3 (4.1 ± 2.7) 0.604
total score 23 (24.7 ± 14.6) 23 (22.4 ± 12.3) 0.434
*; p < 0.05.
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the next day) and 6 (Careful about drinking water) showed
improvement, decreasing significantly from 1.60 ± 1.30 to
1.13 ± 0.99 (P = 0.048) and 2.20 ± 1.52 to 1.73 ± 1.28 (P =
0.0480), respectively (Table 4). There were no differences
between the types of alpha-blockers in terms of the effec-
tiveness against nocturia. A total of 13 patients (63.2%)
exhibited a decrease in the number of nocturia episodes
by more than one time. Nine (47.3%) patients exhibited
nocturia one or fewer times per night. (p <0.01). A total of
16 patients (84.2%) wished to continue taking ramelteon
because they felt that their urinary pattern was more con-
venient than before. On the other hand, three patients
(15.8%) did not want to continue taking ramelteon be-
cause they felt that there had been no changes after
adding ramelteon to their medications. Because of the
small sample size in this study, we could not predict the
patients who were likely to respond to ramelteon.
Two patients developed dizziness within a few days
after starting ramelteon therapy; however, both patients
recovered from dizziness within three to five days with-
out discontinuing ramelteon. The remaining patients
had no adverse drugs-related events.
Discussion
We evaluated the impact of ramelteon on nocturia in
patients with BPH taking an α1-blocker. BPH can induceTable 3 Pre and post OABSS
Variables Median (mean±SD) P value
Pre Post
Q1 1 (0.9 ± 0.3) 1 (0.8 ± 0.4) 0.083
Q2 3 (2.6 ± 0.5) 2 (2.1 ± 0.6) 0.011*
Q3 2 (2.0 ± 1.4) 1.5 (1.8 ± 1.5) 0.429
Q4 0 (0.8 ± 1.1) 0 (0.8 ± 1.2) 1.000
total score 6 (6.3 ± 2.2) 4.5 (5.4 ± 2.2) 0.027*
*; p < 0.05.bladder outlet obstruction and cause secondary bladder
overactivity and a diminution of functional bladder cap-
acity, the last two of which may result in storage symp-
toms including nocturia [20]. α1-blockers are the most
common treatment for lower urinary tract symptoms
(LUTS) in men because they relax prostate smooth
muscle and decrease urethral resistance [21]. All cur-
rently available α1-blockers have similar efficacy and im-
prove symptoms by approximately 35% and maximum
urinary flow rate by 1.8–2.5 mL/s. [21] α1-blockers have
been shown most effective in treating LUTS associated
with BPH [22-24]. Nocturia is one of the LUTS, and a
variety of factors can contribute to nocturia, including
polyuria, nocturnal polyuria, sleep disorder, medication,
bladder storage disorder (BPH, OAB, interstitial cystitis,
etc.), and advanced age [25]. In addition, medical and
surgical treatment for nocturia has been reported to be
less satisfactory than treatment of other LUTS [8,26].
The effectiveness of hypnotic or non-steroidal anti-
inflammatory drugs has been reported; however, such
drugs have positional side effects including affinity for
benzodiazepine which is associated with adverse effects
on cognitive function with the potential for abuse, dys-
pepsia, and nephropathy. For ramelteon on the other
hand, both safety with chronic insomnia have been
reported in Japanese patients [12,13,27]. Therefore, we
selected ramelteon for the BPH patients with nocturia.
In this study, however, uroflowmetry findings after treat-
ment were only checked in three patients, and no differ-
ences were found.
Nocturia is assessed in IPSS question 7, the mean
score of which decreased significantly from 2.88 to 2.41
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for 1 month. However, the impact of nocturia may not
be fully captured by the IPSS questionnaire alone.
Chapple et al. reported that the IPSS does not show
how nocturia decreases sleep quality or how decreasing
sleep quality affects QoL [19]. Therefore, a thorough
evaluation of any treatment of nocturia requires the use
of a method to measure the treatment impact on sleep
quality and the QoL [19]. The International Consultation
on Incontinence Questionnaire (ICIQ) N-QOL instru-
ment, developed by Abraham et al., is an easily adminis-
tered, self-completed questionnaire that specifically
assesses the impact of nocturia on the QoL [28]. In
2009, Yoshida et al. validated a Japanese version of the N-
QOL. In the present study, the total score on the Japanese
N-QOL did not change significantly with ramelteon, but
the mean scores for questions 2 (Low in energy the next
day) and 6 (Careful about drinking water) did. Question
2 might be related to the pharmacological effect of
ramelteon’s association with circadian rhythm. Melatonin
is currently the most accurate marker of human circadian
pacemaker activity [29]. With regard to the clinical guide-
lines for nocturia, most patients with nocturia were
coached by lifestyle guidance and behavioral therapy in-
cluding “Careful about water intake”, which is the same
question of N-QOL Q6 issued by urologists [25]. As a re-
sult of decreased nocturia, we speculate that patients were
not concerned about drinking water.
The OABSS, originally developed in Japan, is a 4-item
questionnaire to express OAB symptoms on a single scale
[30]. The OABSS question items address individual symp-
toms: daytime frequency, nighttime frequency, urgency,
and urgency incontinence. Gotoh et al. reported that
OABSS is a useful tool for assessing the effects of treat-
ment on OAB symptoms and responsive to treatment-
related changes [31]. In the present study, total score and
the score of nighttime frequency (OABSS question 2) de-
creased significantly (P = 0.01, 0.027 respectively).
Yun et al. reported that zolpidem combined with an
α1-blocker was associated with decreased nocturia. Kaye
et al. reported that oxazepam and naproxem, among five
different sedatives and analgesics, significantly decreased
nocturia [17]. Shimizu et al. reported that ramelteon de-
creased nocturia in a cohort of 49 patients, including pa-
tients with insomnia with prostate cancer and BPH, and
those who had undergone radical prostatectomy [10].
The number of nocturia episodes was decreased from
3.1 to 2.2 per night in that study (P < 0.001). Our results
support these data. The authors of that study also
showed that ramelteon increased the nighttime bladder
capacity from 181.4 to 201.1 cc (P < 0.05) [10]. A ran-
domized study to confirm the effectiveness of ramelteon
is needed. In the Japanese general population, the preva-
lence of insomnia was calculated to be about 20% and30% in individuals aged 60 years and older [32,33].
Among widely used drugs, benzodiazepine receptor ago-
nists exert their hypnotic effects through binding to the
gamma-aminobutyric acid (GABA)-a receptor complex
in the brain [34]. However, this mechanism of action of
the benzodiazepines can lead to impairments in cogni-
tive and psychomotor functions and increase the poten-
tial for dependence and withdrawal symptoms, including
rebound insomnia [34]. Zopiclone also binds to GABAa
receptors but differs from the benzodiazepines in the
subtype of receptor it binds [25,26]. Moreover, it has a
similar efficacy but is associated less frequently with
next-day sedation and carries a lower risk of dependence
[34,35].
Melatonin is a neurohormone secreted by the pineal
gland that is involved in regulating the sleep-wake cycle
and circadian rhythm [36]. Drake et al. reported the ef-
fectiveness of melatonin for nocturia in a randomized,
double-blind, placebo-controlled crossover study in 20
men [9]. Its secretion is regulated by the suprachiasmatic
nucleus, and the melatonin MT1 and MT2 receptors ap-
pear to be involved in sleep onset, while MT2 receptors
mediate the phase-shifting effect of melatonin on circa-
dian rhythm [12]. Ramelteon, the first melatonin recep-
tor agonist approved for the treatment of insomnia in
the United States and Japan, is an MT1 and MT2 ago-
nist and has a 3- to 5-fold greater affinity for these re-
ceptors than melatonin [11]. However, ramelteon has no
significant affinity for the MT3 receptor, which is located
outside of the central nervous system and is not thought to
be involved with sleep/circadian rhythms [11]. Ramelteon
has no significant affinity for benzodiazepine, dopamine, or
opiate receptors, sites that have been associated with ad-
verse effects on cognitive function and carry the potential
for abuse [11].
Melatonin is safe in older adults and reported adverse
effects are infrequent, although little is known about
long term use or drug interactions [9,37]. Documented
side effects include decreases in body temperature, seda-
tion, headache, depression, tachycardia, and pruritis. In
our study, 2 of 19 (11%) participants experienced dizzi-
ness. Uchiyama et al. reported long-term safety and effi-
cacy of ramelteon treatment for chronic insomnia [13].
This study had some limitations including the small
sample size and the assessment over the short-term of
only one dosage schedule of ramelteon. Previous reports
have shown that naftopidil improves nocturia [38]. In
the present study, all patients had received naftopidil.
Eight patients in the tamsulosin group and two patients
in the silodosin group had received naftopidil at some
stage. These patients had not been satisfied with the effects
of naftopidil. Therefore, they were switched to the another
alpha-blocker. These findings suggest that ramelteon may
be effective for patients who are resistant to naftopidil. In
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using urodynamic study because of invasive examination.
As such, this study provides a useful initial evaluation of
ramelteon in combination with an α1-blocker for the treat-
ment of nocturia. Because this study confirmed a lack of se-
vere side effects of the treatment, we are now conducting a
multicenter, randomized study of ramelteon for nocturia.
Conclusions
Our results showed that ramelteon in combination with
an α1-blocker could be a new option for reducing nocturia
in men with BPH.
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